ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Isotope Technologies Munich (ITM), a German radiopharmaceutical firm, and Canadian Nuclear Laboratories (CNL) are forming a joint venture for the industrial-scale production of actinium-225 (225Ac). The rare, α-emitting medical radioisotope is of interest as a precision oncology therapy. The venture, Actineer, plans to build a dedicated actinium production facility in an unspecified location. It will begin supplying 225Ac in the interim; CNL will provide starting material for irradiation at its laboratory in Chalk River, Ontario, and ITM will process the resulting 225Ac to pharmaceutical-grade material. CNL operates a national laboratory at Chalk River on behalf of Atomic Energy of Canada.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter